Description
Trade name:
Yasmin
Compound:
ethinyl estradiol 0.03 mg
drospirenone 3 mg
Auxiliary components:
lactose monohydrate , corn starch, pregelatinized corn starch, povidone K25, magnesium stearate.
Properties:
Yasmin® is a low-dose monophasic oral combined estrogen-progestogen contraceptive drug.
The contraceptive effect of combined oral contraceptives (COCs) is based on the interaction of various factors, the most important of which are suppression of ovulation, increased viscosity of cervical secretions and changes in the endometrium.
When Yasmin® is used correctly, the Pearl Index (an indicator reflecting the number of pregnancies in 100 women using the contraceptive during the year) is less than 1. If tablets are missed or used incorrectly, the Pearl Index may increase.
In women taking COCs, the menstrual cycle becomes more regular, painful menstrual-like bleeding is observed less often, the intensity and duration of bleeding decreases, resulting in a reduced risk of iron deficiency anemia. There is also data on a reduced risk of endometrial and ovarian cancer when taking COCs. Drospirenone, which is part of the drug Yasmin®, has antimineralocorticoid activity and is able to prevent weight gain and the occurrence of other symptoms (eg, edema) associated with estrogen-dependent fluid retention. Drospirenone has a positive effect on premenstrual syndrome. In combination with ethinyl estradiol, drospirenone demonstrates a favorable effect on the lipid profile, characterized by an increase in HDL. Drospirenone also has antiandrogenic activity and helps reduce acne, oily skin and hair (seborrhea). These features of drospirenone should be taken into account when choosing a contraceptive for women with hormone-dependent fluid retention, as well as women with acne and seborrhea.
Drospirenone does not have androgenic, estrogenic, glucocorticoid and antiglucocorticoid activity. All this, combined with antimineralocorticoid and antiandrogenic action, provides drospirenone with a biochemical and pharmacological profile similar to natural progesterone.
Indications:
Contraception.
Method of administration and dosage:
A calendar pack of Yasmin® contains 21 tablets. Each tablet in the pack is marked with the day of the week on which it should be taken. The tablets should be taken orally every day for 21 days in the order stated on the pack, at approximately the same time each day, with a small amount of water. The tablet-taking from the next pack should be started after a 7-day tablet-free interval, during which a withdrawal bleed usually occurs. This usually starts 2-3 days after taking the last tablet and may not stop before the next pack is started. After the 7-day tablet-free interval, the tablet-taking from the next pack should be started even if the withdrawal bleed has not yet stopped. This means that the tablet-taking from the new pack should be started on the same day of the week, and that the withdrawal bleed will occur on approximately the same day of the week each month.
Start taking Yasmin®:
If no hormonal contraceptive was used in the previous month
You should start taking Yasmin® on day 1 of your menstrual cycle (i.e. day 1 of your menstrual bleeding). You should take the tablet that is marked with the corresponding day of the week. Then you should take the tablets in order. It is permissible to start taking them on days 2-5 of your menstrual cycle, but in this case it is recommended to additionally use a barrier method of contraception during the first 7 days of taking the tablets from the first pack.
Taking missed pills:
If the delay in taking the drug is less than 12 hours, contraceptive protection is not reduced. The woman should take the tablet as soon as possible, the next tablet is taken at the usual time.
If you are more than 12 hours late taking the pill, contraceptive protection is reduced. The more pills you miss, and the closer the missed pill is to the 7-day break in taking pills, the greater the chance of pregnancy.
It is important to remember:
Taking the drug should never be interrupted for more than 7 days.
7 days of continuous tablet intake is required to achieve adequate suppression of the hypothalamic-pituitary-ovarian axis.
Contraindications:
– migraine with focal neurological symptoms currently or in history;
– diabetes mellitus with vascular complications;
-pancreatitis with severe hypertriglyceridemia at present or in the anamnesis;
– liver failure and severe liver disease (until normalization of liver function tests);
– severe or acute renal failure;
– vaginal bleeding of unknown origin;
-pregnancy or suspicion of it;
– breastfeeding period;
Precautions:
The increased risk of thromboembolism in the postpartum period should be taken into account.
Peripheral circulatory disorders may also be observed in diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel diseases (Crohn’s disease or ulcerative colitis), and sickle cell anemia.
An increase in the frequency and severity of migraine during the use of COCs (which may precede cerebrovascular accidents) is a reason for immediate discontinuation of these drugs.
Side effects:
Headache, lethargy, drowsiness.
Storage method:
At a temperature not exceeding 30 degrees. In a dry place.
